$FOXO
FOXO TECHNOLOGIES INC. Stock $foxo

$foxo Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000121390024050377 Filed on June 06, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$28.00K	$110.0K	$145.0K
YoY Change	133.33%	-73.81%	-71.62%
Cost Of Revenue	$31.00K	$62.00K	$132.0K
YoY Change	158.33%	-81.76%	-74.17%
Gross Profit	-$3.000K	$48.00K	$13.00K
YoY Change		-31.43%	-92.22%
Gross Profit Margin	-10.71%	43.64%	8.97%
Selling, General & Admin	$1.474M	$4.298M	$19.40M
YoY Change	-63.18%	-62.95%	-28.67%
% of Gross Profit		8954.17%	149223.08%
Research & Development	$104.0K	-$24.00K	$901.0K
YoY Change	-68.77%	-102.7%	-70.43%
% of Gross Profit		-50.0%	6930.77%
Depreciation & Amortization	$52.00K	$28.00K	$1.279M
YoY Change	-79.2%	-97.89%	-13.99%
% of Gross Profit		58.33%	9838.46%
Operating Expenses	$1.617M	$3.732M	$22.20M
YoY Change	-78.77%	-83.47%	-44.96%
Operating Profit	-$1.589M	-$3.684M	-$22.19M
YoY Change	-79.11%	-83.63%	-44.76%
Interest Expense	-$542.0K	-$199.0K	-$1.064M
YoY Change	-210.16%	-99.22%	-173.89%
% of Operating Profit
Other Income/Expense, Net	-$575.0K	$24.00K	-$4.263M
YoY Change	-591.45%	-140.0%	-175.46%
Pretax Income	-$2.164M	-$3.859M	-$26.45M
YoY Change	-80.83%	-91.97%	-72.23%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$2.163M	-$4.771M	-$26.45M
YoY Change	-80.85%	-90.07%	-72.23%
Net Earnings / Revenue	-7725.0%	-4337.27%	-18242.07%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.24	-$0.70	-$7.08
COMMON SHARES
Basic Shares Outstanding	10.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.00K	$38.00K	$38.00K
YoY Change	-85.0%	-99.31%	-99.31%
Cash & Equivalents	$33.00K	$38.00K	$38.00K
Short-Term Investments
Other Short-Term Assets	$104.0K	$109.0K	$195.0K
YoY Change	-0.95%	-4.39%	-96.44%
Inventory		$0.00	$0.00
Prepaid Expenses	$76.00K	$86.00K
Receivables	$276.0K
Other Receivables	$0.00
Total Short-Term Assets	$489.0K	$233.0K	$233.0K
YoY Change	-85.31%	-98.11%	-98.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$227.0K	$14.00K
YoY Change
Goodwill	$2.369M
YoY Change
Intangibles	$2.363M	$378.0K
YoY Change	395.39%	-81.5%
Long-Term Investments
YoY Change
Other Assets		$114.0K	$114.0K
YoY Change		-99.46%	-99.46%
Total Long-Term Assets	$6.417M	$492.0K	$492.0K
YoY Change	792.49%	-97.87%	-97.87%
TOTAL ASSETS
Total Short-Term Assets	$489.0K	$233.0K	$233.0K
Total Long-Term Assets	$6.417M	$492.0K	$492.0K
Total Assets	$6.906M	$725.0K	$725.0K
YoY Change	70.64%	-97.95%	-97.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.307M	$4.556M	$4.556M
YoY Change	31.98%	31.45%	31.3%
Accrued Expenses	$1.954M	$1.696M	$3.986M
YoY Change	39.67%	62.3%	158.83%
Deferred Revenue
YoY Change
Short-Term Debt	$7.982M	$0.00	$0.00
YoY Change
Long-Term Debt Due		$4.203M	$4.203M
YoY Change		198.09%	198.09%
Total Short-Term Liabilities	$21.31M	$14.34M	$14.34M
YoY Change	109.75%	107.38%	107.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$219.0K	$489.0K	$489.0K
YoY Change	-76.2%	-97.56%	-97.56%
Total Long-Term Liabilities	$219.0K	$489.0K	$489.0K
YoY Change	-76.2%	-97.76%	-97.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.31M	$14.34M	$14.34M
Total Long-Term Liabilities	$219.0K	$489.0K	$489.0K
Total Liabilities	$23.07M	$14.83M	$14.83M
YoY Change	108.3%	-48.34%	-48.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$181.7M	-$177.1M
YoY Change	7.75%	20.26%
Common Stock	$1.000K	$1.000K
YoY Change	-80.0%	-66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$16.13M	-$14.10M	-$14.10M
YoY Change
Total Liabilities & Shareholders Equity	$6.906M	$725.0K	$725.0K
YoY Change	70.64%	-97.95%	-97.95%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.163M	-$4.771M	-$26.45M
YoY Change	-80.85%	-90.07%	-72.23%
Depreciation, Depletion And Amortization	$52.00K	$28.00K	$1.279M
YoY Change	-79.2%	-97.89%	-13.99%
Cash From Operating Activities	-$1.165M	-$480.0K	-$6.645M
YoY Change	-39.95%	-90.94%	-72.03%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$259.0K	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$259.0K	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.454M	476.0K	$1.168M
YoY Change		-4.8%	-95.19%
NET CHANGE
Cash From Operating Activities	-1.165M	-480.0K	-$6.645M
Cash From Investing Activities	-259.0K	0.000
Cash From Financing Activities	1.454M	476.0K	$1.168M
Net Change In Cash	30.00K	-4.000K	-$5.477M
YoY Change	-101.55%	-99.92%	308.43%
FREE CASH FLOW
Cash From Operating Activities	-$1.165M	-$480.0K	-$6.645M
Capital Expenditures	$0.00
Free Cash Flow	-$1.165M		-$6.645M
YoY Change	-39.95%		-72.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39783
CY2023	dei	Entity Registrant Name EntityRegistrantName	FOXO TECHNOLOGIES INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1050265
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	729 N. Washington Ave.
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Minneapolis
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55401
CY2023	dei	City Area Code CityAreaCode	(612)
CY2023	dei	Local Phone Number LocalPhoneNumber	562-9447
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	13610030	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10667258	shares
	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023	dei	Auditor Location AuditorLocation	Minneapolis, Minnesota
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5515000	usd
CY2022Q4	us-gaap	Supplies Supplies	1313000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	86000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2686000	usd
CY2022Q4	foxo	Prepaid Consulting Fees PrepaidConsultingFees	2676000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	109000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	114000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	233000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	12304000	usd
CY2022Q4	us-gaap	Reinsurance Recoverables ReinsuranceRecoverables	18573000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	378000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2043000	usd
CY2022Q4	foxo	Cloud Computing Arrangements Noncurrent CloudComputingArrangementsNoncurrent	2225000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	114000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	263000	usd
CY2023Q4	us-gaap	Assets Assets	725000	usd
CY2022Q4	us-gaap	Assets Assets	35408000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4556000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3466000	usd
CY2023Q4	foxo	Senior Paid In Kind Notes SeniorPaidInKindNotes	4203000	usd
CY2022Q4	foxo	Senior Paid In Kind Notes SeniorPaidInKindNotes	1409000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1696000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1045000	usd
CY2023Q4	foxo	Accrued Settlement AccruedSettlement	2260000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	30000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	493000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14336000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6913000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	8000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	311000	usd
CY2022Q4	foxo	Paid In Kind Notes Non Current PaidInKindNotesNonCurrent	1730000	usd
CY2022Q4	foxo	Policy Reserves PolicyReserves	18573000	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	481000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	1173000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14825000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	28700000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	214077	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	162959000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	153939000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177060000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147231000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-14100000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6708000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	725000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35408000	usd
CY2023	us-gaap	Revenues Revenues	145000	usd
CY2022	us-gaap	Revenues Revenues	511000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	132000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	344000	usd
CY2023	us-gaap	Gross Profit GrossProfit	13000	usd
CY2022	us-gaap	Gross Profit GrossProfit	167000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	901000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3047000	usd
CY2023	foxo	Management Contingent Share Plans ManagementContingentSharePlans	-732000	usd
CY2022	foxo	Management Contingent Share Plans ManagementContingentSharePlans	10091000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2633000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1370000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19399000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25826000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	22201000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	40334000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-22188000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-40167000	usd
CY2022	foxo	Noncash Change In Fair Value Of Convertible Debentures NoncashChangeInFairValueOfConvertibleDebentures	-28180000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-303000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2076000	usd
CY2023	foxo	Loss From Pik Note Amendment And2022 Debenture Release LossFromPIKNoteAmendmentAnd2022DebentureRelease	3521000	usd
CY2022	foxo	Forward Purchase Agreement Expense ForwardPurchaseAgreementExpense	27337000	usd
CY2023	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	1064000	usd
CY2022	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	1440000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-207000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4263000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-55088000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-26451000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-95255000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-26451000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-95255000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3378000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29829000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-95255000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-25220000	usd
CY2022	foxo	Adjustments To Additional Paid In Capital Lease Contributions AdjustmentsToAdditionalPaidInCapitalLeaseContributions	225000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	716000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	507000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	6900000	usd
CY2022	foxo	Stock Issued During Period Value Conversion Of Bridge Loans StockIssuedDuringPeriodValueConversionOfBridgeLoans	88975000	usd
CY2022	foxo	Stock Issued During Period Value Conversion Of Existing Class A Common Stock StockIssuedDuringPeriodValueConversionOfExistingClassACommonStock	1000	usd
CY2022	foxo	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	19689000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	10364000	usd
CY2022	foxo	Stock Issued During Period Value Cantor Commitment Fee StockIssuedDuringPeriodValueCantorCommitmentFee	1600000	usd
CY2022	foxo	Stock Issued During Period Value Vendor Share Issuance StockIssuedDuringPeriodValueVendorShareIssuance	376000	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1156000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6708000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29829000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	-269000	usd
CY2023	foxo	Stock Issued During Period Value Private Placements Net Of Issuance Costs StockIssuedDuringPeriodValuePrivatePlacementsNetOfIssuanceCosts	863000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	12000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	650000	usd
CY2023	foxo	Stock Issued During Period Value Issuance Of Shares To Msk StockIssuedDuringPeriodValueIssuanceOfSharesToMSK	234000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	409000	usd
CY2023	foxo	Stock Issued During Period Value Issuance Of Shares To Joseph Gunnar StockIssuedDuringPeriodValueIssuanceOfSharesToJosephGunnar	221000	usd
CY2023	foxo	Stock Issued During Period Value2022 Debenture Release StockIssuedDuringPeriodValue2022DebentureRelease	2182000	usd
CY2023	foxo	Stock Issued During Period Value Pik Note Amendment StockIssuedDuringPeriodValuePIKNoteAmendment	1339000	usd
CY2023	foxo	Stock Issued During Period Value Exchange Offer StockIssuedDuringPeriodValueExchangeOffer	2466000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	912000	usd
CY2023	foxo	Stock Issued During Period Value Reverse Stock Split Adjustments StockIssuedDuringPeriodValueReverseStockSplitAdjustments	2000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-14100000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-26451000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-95255000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1279000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1487000	usd
CY2023	foxo	Loss From Pik Note Amendment And2022 Debenture Release LossFromPIKNoteAmendmentAnd2022DebentureRelease	3521000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2633000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1370000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	381000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11035000	usd
CY2022	foxo	Cantor Commitment Fee Paid In Common Stock CantorCommitmentFeePaidInCommonStock	1600000	usd
CY2022	foxo	Loss On Settlement Of The Forward Purchase Agreement Paid In Common Stock LossOnSettlementOfTheForwardPurchaseAgreementPaidInCommonStock	270000	usd
CY2022	foxo	Release Of Forward Purchase Agreement Collateral Upon Cancellation ReleaseOfForwardPurchaseAgreementCollateralUponCancellation	26773000	usd
CY2022	foxo	Vendor Share Issuance Paid In Common Stock VendorShareIssuancePaidInCommonStock	376000	usd
CY2023	foxo	Amortization Of Consulting Fees Paid In Common Stock AmortizationOfConsultingFeesPaidInCommonStock	2221000	usd
CY2022	foxo	Amortization Of Consulting Fees Paid In Common Stock AmortizationOfConsultingFeesPaidInCommonStock	4679000	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	865000	usd
CY2022	foxo	Change In Fair Value Of Convertible Debentures ChangeInFairValueOfConvertibleDebentures	28180000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-303000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2076000	usd
CY2022	foxo	Conversion Of Accrued Interest ConversionOfAccruedInterest	593000	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	616000	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	130000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	448000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	91000	usd
CY2022	foxo	Contributions In The Form Of Rent Payments ContributionsInTheFormOfRentPayments	225000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	28000	usd
CY2022	foxo	Accretion Of Operating Lease Liabilities AccretionOfOperatingLeaseLiabilities	28000	usd
CY2022	foxo	Recognition Of Prepaid Offering Costs Upon Election Of Fair Value Option RecognitionOfPrepaidOfferingCostsUponElectionOfFairValueOption	107000	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	125000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	6000	usd
CY2023	us-gaap	Increase Decrease In Materials And Supplies IncreaseDecreaseInMaterialsAndSupplies	-1313000	usd
CY2022	us-gaap	Increase Decrease In Materials And Supplies IncreaseDecreaseInMaterialsAndSupplies	1018000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3055000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2832000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-5000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	91000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	100000	usd
CY2022	foxo	Increase Decrease In Cloud Computing Arrangements IncreaseDecreaseInCloudComputingArrangements	1773000	usd
CY2023	us-gaap	Increase Decrease In Reinsurance Payables IncreaseDecreaseInReinsurancePayables	18573000	usd
CY2022	us-gaap	Increase Decrease In Reinsurance Payables IncreaseDecreaseInReinsurancePayables	890000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1297000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	127000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2350000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2336000	usd
CY2023	foxo	Increase Decrease In Policy Reserves IncreaseDecreaseInPolicyReserves	18573000	usd
CY2022	foxo	Increase Decrease In Policy Reserves IncreaseDecreaseInPolicyReserves	890000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6645000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23760000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	110000	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	1760000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1870000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	28000000	usd
CY2022	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	507000	usd
CY2022	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	3458000	usd
CY2022	foxo	Reverse Recapitalization Proceeds ReverseRecapitalizationProceeds	23237000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-30561000	usd
CY2022	foxo	Forward Purchase Agreement Collateral Release ForwardPurchaseAgreementCollateralRelease	2362000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1176000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	299000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	540000	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	291000	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-1160000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1168000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24289000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5477000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1341000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5515000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6856000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5515000	usd
CY2022	foxo	Conversion Of Debt ConversionOfDebt	88382000	usd
CY2023	foxo	Deemed Dividends In Connection With Exchange Offer DeemedDividendsInConnectionWithExchangeOffer	3378000	usd
CY2023	foxo	Pik Note Amendment PIKNoteAmendment	1339000	usd
CY2023	foxo	Debenture Release DebentureRelease	2182000	usd
CY2022	foxo	Conversion Of Preferred Stock ConversionOfPreferredStock	21854000	usd
CY2022	foxo	Accrued Internal Use Softwares AccruedInternalUseSoftwares	239000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1219000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -45.35pt"><span style="text-decoration:underline">Note 1 DESCRIPTION OF BUSINESS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOXO Technologies Inc. (“FOXO” or the “Company”), formerly known as Delwinds Insurance Acquisition Corp. (“Delwinds”), a Delaware corporation, was originally formed in April 2020 as a publicly traded special purpose company for the purpose of effecting a merger, capital stock exchange, asset acquisition, reorganization, or similar business combination involving one or more businesses. FOXO is commercializing epigenetic biomarker technology to support groundbreaking scientific research and disruptive next-generation business initiatives. The Company applies automated machine learning and artificial intelligence (“AI”) technologies to discover epigenetic biomarkers of human health, wellness and aging. On October 29, 2023, the Company entered into a Letter Agreement with KR8 AI Inc. to develop a Direct-to-Consumer app (iOS and Android) combining its AI Machine Learning technology to provide a commercial application of FOXO’s epigenetic biomarker technology as a subscription consumer engagement platform. The Letter Agreement limits the distribution of any such apps to consumers in North America. In January 2024, the Letter Agreement was replaced by a definitive license agreement as more fully discussed in Note 17.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Segments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company manages and classifies its business into two reportable business segments, FOXO Labs and FOXO Life. While Company has decided to pause sales of new life insurance products, it still intends to continue to classify its business into the two reportable business segments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Business Combination</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2022, Delwinds entered into a definitive Agreement and Plan of Merger, dated as of February 24, 2022, as amended on April 26, 2022, July 6, 2022 and August 12, 2022 (the “Merger Agreement”), with FOXO Technologies Inc., now known as FOXO Technologies Operating Company (“FOXO Technologies Operating Company”), DWIN Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Delwinds (“Merger Sub”), and DIAC Sponsor LLC (the “Sponsor”), in its capacity as the representative of the stockholders of Delwinds from and after the closing (the “Closing”) of the transactions contemplated by the FOXO Transaction Agreement (collectively, the “Transaction” or the “Business Combination”). Simultaneously with the execution of the Merger Agreement, Delwinds entered into a Common Stock Purchase Agreement (the “ELOC Agreement”) with CF Principal Investments LLC (the “Cantor Investor”), pursuant to which, assuming satisfaction of certain conditions and subject to limitations set forth in the ELOC Agreement, the Company would have the right, from time to time to sell the Cantor Investor up to $40,000 in shares of the Company’s Class A common stock (the “Class A Common Stock”) until the first day of the next month following the 36-month anniversary of when the Securities and Exchange Commission (“SEC”) had declared effective a registration statement covering the resale of such shares of the Company’s Class A Common Stock or until the date on which the facility had been fully utilized, if earlier. The ELOC Agreement was subsequently cancelled. See Note 7 for additional information about the ELOC Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Business Combination was approved by Delwinds’ stockholders on September 14, 2022, and closed on September 15, 2022 (the “Closing Date”) whereby Merger Sub merged into FOXO Technologies Operating Company, with FOXO Technologies Operating Company surviving the merger as a wholly owned subsidiary of the Company (the “Combined Company”), and with FOXO Technologies Operating Company security holders becoming security holders of the Combined Company. Immediately upon the Closing, the name of Delwinds was changed to FOXO Technologies Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Closing, FOXO is a holding company whose wholly-owned subsidiary, FOXO Technologies Operating Company, conducts all of the core business operations. FOXO Technologies Operating Company maintains its two wholly-owned subsidiaries, FOXO Labs Inc. and FOXO Life, LLC. FOXO Labs maintains a wholly-owned subsidiary, Scientific Testing Partners, LLC, while FOXO Life Insurance Company was a wholly-owned subsidiary of FOXO Life, LLC. On February 3, 2023, the Company sold FOXO Life Insurance Company as more fully discussed in Note 13. References to “FOXO” and the “Company” in these consolidated financial statements refer to FOXO Technologies Operating Company and its wholly-owned subsidiaries prior to the Closing and FOXO Technologies Inc. following the Closing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the terms of the Merger Agreement, at Closing, the Company (i) acquired 100% of the issued and outstanding FOXO Technologies Operating Company Class A common stock (the “FOXO Class A Common Stock”) in exchange for equity consideration in the form of the Company’s Class A Common Stock, and (ii) acquired 100% of the issued and outstanding shares of FOXO Technologies Operating Company Class B common stock (the “FOXO Class B Common Stock”) in exchange for equity consideration in the form of the Company’s Class A Common Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immediately prior to the Closing, the following transactions occurred:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">8,000,000 shares of FOXO Technologies Operating Company Series A preferred stock (the “FOXO Preferred Stock”) were exchanged for 8,000,000 shares of FOXO Class A Common Stock.</td></tr></table> <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The 2021 Bridge Debentures (as defined in Note 5) in the principal amount, together with accrued and unpaid interest, of $24,402 were converted into 6,759,642 shares of FOXO Class A Common Stock.</td></tr></table> <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">The holders of the 2022 Bridge Debentures (as defined in Note 5) in the principal amount, together with accrued and unpaid interest, of $34,496 were converted into 7,810,509 shares of FOXO Class A Common Stock.</td></tr></table> <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of and upon the Closing, among other things, (1) all outstanding shares of FOXO Class A Common Stock (after giving effect to the conversion of the FOXO Preferred Stock, the 2021 Bridge Debentures, and 2022 Bridge Debentures into shares of FOXO Class A Common Stock) and FOXO Class B Common Stock were converted into 1,551,871 shares of the Company’s Class A Common Stock, (2) all FOXO options and FOXO warrants outstanding immediately before the Closing (“Assumed Options” and “Assumed Warrants”, as applicable) were assumed and converted, subject to adjustment pursuant to the terms of the Merger Agreement, into options and warrants, respectively, of the Company, exercisable for shares of the Company’s Class A Common Stock and (3) other than the Assumed Options and Assumed Warrants, all other convertible securities and other rights to purchase capital stock of FOXO Technologies Operating Company were retired and terminated, if they were not converted, exchanged or exercised for FOXO Technologies Operating Company stock immediately prior the Closing.</p>
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 reverse stock split
CY2023Q3	foxo	Aggregate Gross Proceeds AggregateGrossProceeds	293500	usd
CY2023Q3	us-gaap	Other Expenses OtherExpenses	217000	usd
CY2023	us-gaap	Business Combination Control Obtained Description BusinessCombinationControlObtainedDescription	Immediately prior to the Closing, the following transactions occurred: ●8,000,000 shares of FOXO Technologies Operating Company Series A preferred stock (the “FOXO Preferred Stock”) were exchanged for 8,000,000 shares of FOXO Class A Common Stock. ●The 2021 Bridge Debentures (as defined in Note 5) in the principal amount, together with accrued and unpaid interest, of $24,402 were converted into 6,759,642 shares of FOXO Class A Common Stock. ●The holders of the 2022 Bridge Debentures (as defined in Note 5) in the principal amount, together with accrued and unpaid interest, of $34,496 were converted into 7,810,509 shares of FOXO Class A Common Stock.
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29829000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-95255000	usd
CY2023Q4	foxo	Working Capital Deficit WorkingCapitalDeficit	14103000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-14100000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6645000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23760000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	28000000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	28000000	usd
CY2023Q4	us-gaap	Other Partners Capital OtherPartnersCapital	300000000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RECLASSIFICATION</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has reclassified an impairment loss presented in the consolidated statement of operations for the year ended December 31, 2022 for comparison purposes.</p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">USE OF ESTIMATES</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Management evaluates these estimates and judgments on an ongoing basis and bases its estimates on experience, current and expected future conditions, third-party evaluations, and various other assumptions that management believes are reasonable under the circumstances. It is reasonably possible that actual experience could differ from the estimates and assumptions utilized. All revisions to accounting estimates are recognized in the period in which the estimates are revised. A description of each critical estimate is incorporated within the discussion of the related accounting policies which follow.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Supplies And Postage Expense SuppliesAndPostageExpense	1313000	usd
CY2023Q4	us-gaap	Sale Leaseback Transaction Net Book Value SaleLeasebackTransactionNetBookValue	23000	usd
CY2023	foxo	Outstanding Balance Percentage OutstandingBalancePercentage	0.0499	pure
CY2023	foxo	Issued And Outstanding Percentage issuedAndOutstandingPercentage	0.0999	pure
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	200000	usd
CY2023	foxo	Proceeds Isssuance Of Cash ProceedsIsssuanceOfCash	186000	usd
CY2023	foxo	Additional Restricted Shares AdditionalRestrictedShares	979000	shares
CY2023	foxo	Net Of Issuance Costs NetOfIssuanceCosts	246000	usd
CY2023Q4	us-gaap	Deposit Contracts Assets DepositContractsAssets	100000	usd
CY2022Q4	us-gaap	Deposit Contracts Assets DepositContractsAssets	200000	usd
CY2023Q3	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	100000	usd
CY2023	us-gaap	Revenues Revenues	145000	usd
CY2022	us-gaap	Revenues Revenues	511000	usd
CY2023	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	2676000	usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	5649000	usd
CY2022	foxo	Contingent Share Plan ContingentSharePlan	80000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	foxo	Aggregate Gross Proceeds AggregateGrossProceeds	450000	usd
CY2023Q3	us-gaap	Other Expenses OtherExpenses	260000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1771000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	106000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	378000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2043000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1257000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1283000	usd
CY2023Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1425000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2633000	usd
CY2022Q3	foxo	Senior Notes Percentage SeniorNotesPercentage	0.15	pure
CY2022Q3	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	2918000	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	540000	usd
CY2023	foxo	Interest Rate InterestRate	1.15
CY2023	foxo	Pik Note Amendment PIKNoteAmendment	1339000	usd
CY2023Q4	us-gaap	Percentage Of Unamortized Film Costs PercentageOfUnamortizedFilmCosts	0.10	pure
CY2023	us-gaap	Deferred Finance Costs Own Share Lending Arrangement Issuance Costs Amortization Expense1 DeferredFinanceCostsOwnShareLendingArrangementIssuanceCostsAmortizationExpense1	1596000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	256000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1339000	usd
CY2023	foxo	Percentage Of Outstanding Principal Balance PercentageOfOutstandingPrincipalBalance	1.30	pure
CY2023Q4	foxo	Senior Paid In Kind Notes SeniorPaidInKindNotes	4203000	usd
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	448000	usd
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	130000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	616000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	91000	usd
CY2023	foxo	Convertible Debentures Issued Percentage ConvertibleDebenturesIssuedPercentage	0.125	pure
CY2023	us-gaap	Interest Expense Subordinated Notes And Debentures InterestExpenseSubordinatedNotesAndDebentures	3656000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	1.30	pure
CY2022Q2	foxo	Aggregate Principal Amount Per Share AggregatePrincipalAmountPerShare	0.035
CY2023	us-gaap	Management Fee Expense ManagementFeeExpense	595000	usd
CY2022Q2	us-gaap	Cash Flows Between Transferee And Transferor Servicing Fees CashFlowsBetweenTransfereeAndTransferorServicingFees	1425000	usd
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	87126	shares
CY2023	foxo	Percentage Of Exceed Outstanding PercentageOfExceedOutstanding	0.1999	pure
CY2023	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	1.324
CY2023Q4	foxo	Percentage Of Exercise Price PercentageOfExercisePrice	1.10	pure
CY2023Q4	foxo	Finders Warrants FindersWarrants	25672	shares
CY2023Q4	us-gaap	Servicing Asset At Fair Value Amount ServicingAssetAtFairValueAmount	12000	usd
CY2023Q3	us-gaap	Legal Fees LegalFees	643000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q2	foxo	Warrants Shares Received WarrantsSharesReceived	48.3	shares
CY2023	us-gaap	Dividend Income Operating Paid In Cash DividendIncomeOperatingPaidInCash	2466000	usd
CY2023	us-gaap	Investment Company Redemption Fee Per Share InvestmentCompanyRedemptionFeePerShare	0.067
CY2023Q4	us-gaap	Share Price SharePrice	1
CY2023	foxo	Shares Subject To Equitable Adjustment SharesSubjectToEquitableAdjustment	920000	shares
CY2023	foxo	Timebased Vesting Description TimebasedVestingDescription	Each restricted share award shall be subject to three service-based vesting conditions: a)Sixty percent (60%) of a participant’s restricted share award will become vested on the third anniversary of the Closing if the participant is still employed by the company on such date (and has been continuously employed by the company from the date of grant through such vesting date). b)An additional twenty percent (20%) of a participant’s restricted share award will become vested on the fourth anniversary of the Closing if the participant is still employed by the company on such date (and has been continuously employed by the company from the date of grant through such vesting date). c)The final twenty percent (20%) of a participant’s restricted share award will become vested on the fifth anniversary of the Closing if the participant is still employed by the company on such date (and has been continuously employed by the company from the date of grant through such vesting date).
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	419132	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	732000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	1	pure
CY2023	foxo	Share Based Compensation Shares Authorized Under Stock Option Plans ShareBasedCompensationSharesAuthorizedUnderStockOptionPlans	119371	shares
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1743	shares
CY2022Q1	foxo	Share Based Compensation Arrangement Additional Stock Options ShareBasedCompensationArrangementAdditionalStockOptions	20418	shares
CY2023	us-gaap	Investment Company Total Return Market Value InvestmentCompanyTotalReturnMarketValue	1	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	276510	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	70.2
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	157139	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	68.15
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	119371	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	73.02
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y2M19D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Other ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther	115616	shares
CY2023	foxo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceExercisable	70.5
CY2023	foxo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Average Remaining Life Years Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAverageRemainingLifeYearsExercisable	P2Y2M8D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	282831	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	65.1
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	20418	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	157.5
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1480	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	65.1
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	25259	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	83.6
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	276510	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	70.2
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y9M7D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Other ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther	248099	shares
CY2022	foxo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceExercisable	67
CY2022	foxo	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Average Remaining Life Years Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAverageRemainingLifeYearsExercisable	P2Y8M1D
CY2023	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.32
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y2M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.70	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0138	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	157.5
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	72000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	110000	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1041000	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	834000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	1113000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	944000	usd
CY2023	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	283000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P0Y6M
CY2023Q4	us-gaap	Preferred Stock Redemption Amount PreferredStockRedemptionAmount	29135000	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	50	shares
CY2023Q4	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	270000	usd
CY2022	foxo	Share Purchase Agreement SharePurchaseAgreement	27337000	usd
CY2023	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	15668	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	434800	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-26451000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-95255000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3378000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29829000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-95255000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	1037875	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	1037875	shares
CY2023Q4	foxo	Assumed Warrants AssumedWarrants	2007848	shares
CY2022Q4	foxo	Assumed Warrants AssumedWarrants	190585	shares
CY2023Q4	foxo	Assumed Option Shares AssumedOptionShares	119371	shares
CY2022Q4	foxo	Assumed Option Shares AssumedOptionShares	296550	shares
CY2023Q4	foxo	Finders Warrants FindersWarrants	25672	shares
CY2023Q4	foxo	Total Antidilutive Shares TotalAntidilutiveShares	3190766	shares
CY2022Q4	foxo	Total Antidilutive Shares TotalAntidilutiveShares	1525010	shares
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	8000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	311000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-303000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2076000	usd
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-28180000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	4802000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	9767000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1653000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4054000	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	6455000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	13821000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	6455000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	13821000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.056	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.09	pure
CY2022	foxo	Effective Income Tax Rate Fair Value Adjustments On Convertible Debentures EffectiveIncomeTaxRateFairValueAdjustmentsOnConvertibleDebentures	-0.071	pure
CY2022	foxo	Effective Income Tax Rate Forward Purchase Agreement EffectiveIncomeTaxRateForwardPurchaseAgreement	-0.085	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.044	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.225	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.145	pure
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	482000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3817000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22873000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17193000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	682000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	1270000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	12000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	7000	usd
CY2023Q4	foxo	Deferred Tax Assests Issuance Fee On Convertible Debentures DeferredTaxAssestsIssuanceFeeOnConvertibleDebentures	2970000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27019000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22287000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27009000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21837000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	10000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	450000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	10000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	450000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	10000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	450000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	83400000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1600000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	81800000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	74500000	usd
CY2023	us-gaap	Sale Of Stock Percentage Of Ownership Before Transaction SaleOfStockPercentageOfOwnershipBeforeTransaction	0.50	pure
CY2023	foxo	Loss Carry Forward Limited Term LossCarryForwardLimitedTerm	P1Y
CY2021Q3	us-gaap	Business Combination Price Of Acquisition Expected BusinessCombinationPriceOfAcquisitionExpected	1155000	usd
CY2021Q3	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	63000	usd
CY2021Q3	us-gaap	Cash Cash	1092000	usd
CY2023	foxo	Reinsure Policies ReinsurePolicies	1	pure
CY2023	foxo	Reinsured Business Percentage ReinsuredBusinessPercentage	1	pure
CY2022Q4	foxo	Policy Reserves PolicyReserves	18573000	usd
CY2022	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	362000	usd
CY2022	us-gaap	Ceded Premiums Earned CededPremiumsEarned	1349000	usd
CY2023Q1	us-gaap	Increase Decrease In Future Policy Benefit Reserves IncreaseDecreaseInFuturePolicyBenefitReserves	18573000	usd
CY2023Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	5000000	usd
CY2023	foxo	Riskbased Capital Percentage RiskbasedCapitalPercentage	3.01	pure
CY2022Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	5000000	usd
CY2022Q4	us-gaap	Cash Cash	100000	usd
CY2023Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	4751000	usd
CY2023	us-gaap	Reinsurance Retention Policy Reinsured Risk Percentage ReinsuranceRetentionPolicyReinsuredRiskPercentage	1	pure
CY2023	us-gaap	Statutory Accounting Practices Statutory Net Income Amount StatutoryAccountingPracticesStatutoryNetIncomeAmount	105000	usd
CY2022	us-gaap	Statutory Accounting Practices Statutory Net Income Amount StatutoryAccountingPracticesStatutoryNetIncomeAmount	105000	usd
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	1575000	usd
CY2022Q4	foxo	Performancebased Conditions Vested PerformancebasedConditionsVested	576000	usd
CY2022Q4	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	999000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	462000	usd
CY2023	foxo	Percentage Of Subcriber Revenue PercentageOfSubcriberRevenue	0.15	pure
CY2023	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	25000	usd
CY2023Q4	us-gaap	Trading Liabilities Fair Value Disclosure TradingLiabilitiesFairValueDisclosure	1000000	usd
CY2023Q4	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	0	usd
CY2022Q4	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	62000	usd
CY2023Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	0	usd
CY2022Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	14246000	usd
CY2022Q4	foxo	Deferred Annuity Contracts DeferredAnnuityContracts	4327000	usd
CY2021Q4	foxo	Deferred Annuity Contracts DeferredAnnuityContracts	4717000	usd
CY2023	foxo	Deposits Received DepositsReceived	27000	usd
CY2022	foxo	Deposits Received DepositsReceived	7000	usd
CY2022	us-gaap	Interest Credited To Policy Owner Account InterestCreditedToPolicyOwnerAccount	139000	usd
CY2023	foxo	Withdrawals Withdrawals	-82000	usd
CY2022	foxo	Withdrawals Withdrawals	-536000	usd
CY2023	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	4272000	usd
CY2022Q4	foxo	Deferred Annuity Contracts DeferredAnnuityContracts	4327000	usd
CY2022Q4	us-gaap	Reinsurance Recoverables ReinsuranceRecoverables	18573000	usd
CY2023	foxo	Merger Consideration MergerConsideration	200000	usd
CY2023Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	4751000	usd
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	251000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1313000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1279000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2633000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-303000	usd
CY2023	foxo	Loss From Pik Note Amendment And2022 Debenture Release LossFromPIKNoteAmendmentAnd2022DebentureRelease	3521000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1487000	usd
CY2023	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	2260000	usd
CY2022	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	0	usd
CY2022Q1	foxo	Outstanding Balance Percentage OutstandingBalancePercentage	20.21	pure
CY2023	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	6207000	usd
CY2023	foxo	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.25	pure
CY2023	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	300000	usd
CY2023	foxo	Revenues Received Percentage RevenuesReceivedPercentage	0.15	pure
CY2022	foxo	Debenture Release DebentureRelease		usd
CY2023	foxo	Conversion Of Preferred Stock ConversionOfPreferredStock		usd
CY2023Q4	foxo	Trading Value Percentage TradingValuePercentage	3	pure
CY2023	foxo	Common Stock Issued And Outstanding Shares Percentage CommonStockIssuedAndOutstandingSharesPercentage	0.0999	pure
CY2023	foxo	Percentage Of Exercise Price PercentageOfExercisePrice	1.10	pure
CY2023Q4	us-gaap	Supplies Supplies		usd
CY2023Q4	foxo	Prepaid Consulting Fees PrepaidConsultingFees		usd
CY2023Q4	us-gaap	Reinsurance Recoverables ReinsuranceRecoverables		usd
CY2023Q4	foxo	Cloud Computing Arrangements Noncurrent CloudComputingArrangementsNoncurrent		usd
CY2022Q4	foxo	Accrued Settlement AccruedSettlement		usd
CY2023Q4	foxo	Paid In Kind Notes Non Current PaidInKindNotesNonCurrent		usd
CY2023Q4	foxo	Policy Reserves PolicyReserves		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2023	foxo	Noncash Change In Fair Value Of Convertible Debentures NoncashChangeInFairValueOfConvertibleDebentures		usd
CY2022	foxo	Loss From Pik Note Amendment And2022 Debenture Release LossFromPIKNoteAmendmentAnd2022DebentureRelease		usd
CY2023	foxo	Forward Purchase Agreement Expense ForwardPurchaseAgreementExpense		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2022	foxo	Loss From Pik Note Amendment And2022 Debenture Release LossFromPIKNoteAmendmentAnd2022DebentureRelease		usd
CY2023	foxo	Cantor Commitment Fee Paid In Common Stock CantorCommitmentFeePaidInCommonStock		usd
CY2023	foxo	Loss On Settlement Of The Forward Purchase Agreement Paid In Common Stock LossOnSettlementOfTheForwardPurchaseAgreementPaidInCommonStock		usd
CY2023	foxo	Release Of Forward Purchase Agreement Collateral Upon Cancellation ReleaseOfForwardPurchaseAgreementCollateralUponCancellation		usd
CY2023	foxo	Vendor Share Issuance Paid In Common Stock VendorShareIssuancePaidInCommonStock		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2023	foxo	Change In Fair Value Of Convertible Debentures ChangeInFairValueOfConvertibleDebentures		usd
CY2023	foxo	Conversion Of Accrued Interest ConversionOfAccruedInterest		usd
CY2023	foxo	Contributions In The Form Of Rent Payments ContributionsInTheFormOfRentPayments		usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
CY2023	foxo	Accretion Of Operating Lease Liabilities AccretionOfOperatingLeaseLiabilities		usd
CY2023	foxo	Recognition Of Prepaid Offering Costs Upon Election Of Fair Value Option RecognitionOfPrepaidOfferingCostsUponElectionOfFairValueOption		usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets		usd
CY2023	foxo	Increase Decrease In Cloud Computing Arrangements IncreaseDecreaseInCloudComputingArrangements		usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023	us-gaap	Payments For Software PaymentsForSoftware		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants		usd
CY2023	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt		usd
CY2023	foxo	Reverse Recapitalization Proceeds ReverseRecapitalizationProceeds		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	foxo	Forward Purchase Agreement Collateral Release ForwardPurchaseAgreementCollateralRelease		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023	foxo	Conversion Of Debt ConversionOfDebt		usd
CY2022	foxo	Deemed Dividends In Connection With Exchange Offer DeemedDividendsInConnectionWithExchangeOffer		usd
CY2022	foxo	Pik Note Amendment PIKNoteAmendment		usd
CY2023	foxo	Accrued Internal Use Softwares AccruedInternalUseSoftwares		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2023	foxo	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022	foxo	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable		usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2022Q4	foxo	Finders Warrants FindersWarrants		shares
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	foxo	Effective Income Tax Rate Fair Value Adjustments On Convertible Debentures EffectiveIncomeTaxRateFairValueAdjustmentsOnConvertibleDebentures		pure
CY2023	foxo	Effective Income Tax Rate Forward Purchase Agreement EffectiveIncomeTaxRateForwardPurchaseAgreement		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022Q4	foxo	Deferred Tax Assests Issuance Fee On Convertible Debentures DeferredTaxAssestsIssuanceFeeOnConvertibleDebentures		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Interest Credited To Policy Owner Account InterestCreditedToPolicyOwnerAccount		usd
CY2022	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1		usd
CY2023Q4	foxo	Deferred Annuity Contracts DeferredAnnuityContracts		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001812360

Files In Submission

Name	View Source	Status
foxo-20231231_cal.xml	Edgar Link	unprocessable
0001213900-24-050377-index-headers.html	Edgar Link	pending
0001213900-24-050377-index.html	Edgar Link	pending
0001213900-24-050377.txt	Edgar Link	pending
0001213900-24-050377-xbrl.zip	Edgar Link	pending
ea0206840-10k_foxotech.htm	Edgar Link	pending
ea020684001ex23-7_foxotech.htm	Edgar Link	pending
ea020684001ex31-1_foxotech.htm	Edgar Link	pending
ea020684001ex31-2_foxotech.htm	Edgar Link	pending
ea020684001ex32-1_foxotech.htm	Edgar Link	pending
ea020684001ex97-1_foxotech.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
foxo-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
foxo-20231231_lab.xml	Edgar Link	unprocessable
foxo-20231231_def.xml	Edgar Link	unprocessable
foxo-20231231_pre.xml	Edgar Link	unprocessable
ea0206840-10k_foxotech_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOXO
FOXO TECHNOLOGIES INC. Stock $foxo

2024 Q2 Form 10-K Financial Statement

#000121390024050377 Filed on June 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOXO FOXO TECHNOLOGIES INC. Stock $foxo

2024 Q2 Form 10-K Financial Statement

#000121390024050377 Filed on June 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOXO
FOXO TECHNOLOGIES INC. Stock $foxo